San Francisco-based Swander Pace Capital has sold Insight Pharmaceuticals to Prestige Brands for $750 million.
The sale of Insight represents the firm’s second successful platform investment in the OTC industry.
Sources familiar with the transaction say that the deal will generate a 4x return.
Swander Pace and its representatives declined to comment on the transaction.
Insight Pharmaceuticals is the maker of several over the counter personal health brands including e.p.t®, a home pregnancy testing brand.
The Ontario Teachers’ Pension Plan was a co-investor in the company when Swander Pace acquired Insight from Allied Capital Corp., a listed business development company in 2009.
Prior to ownership by Allied, the company was held by Catterton Partners.
In April, Swander closed its fifth buyout fund – SPC Partners V on $350 million, according to Private Equity International’s research and analytics division.